₹ 7.8 Cr
Volume Transacted
(Nov 21, 2024)
64.9 K
Stocks Traded
(Nov 21, 2024)
Last Updated on: Nov 22, 2024
Dr Reddys Laboratories Ltd
NSE: DRREDDY
YEARLOW
₹ 1074.35
Last updated on: Nov 21, 2024
Open Demat Account
Enter your mobile no. to continue
+91
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
No data available
* All values are consolidated
Last Updated time:
The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.
1M
1Y
3Y
5Y
Date | Price (₹) | Day Open (₹) | Day High (₹) | Day Low (₹) |
---|
21 Nov 2024 | 1194.55 | 1175.05 | 1207.2 | 1175 |
19 Nov 2024 | 1213.95 | 1191.05 | 1231.75 | 1187.2 |
18 Nov 2024 | 1193.35 | 1195.6 | 1221 | 1171 |
14 Nov 2024 | 1226.05 | 1254.55 | 1254.55 | 1222.25 |
13 Nov 2024 | 1245.7 | 1259.3 | 1263.5 | 1239 |
12 Nov 2024 | 1263.1 | 1288 | 1288.2 | 1257 |
11 Nov 2024 | 1288.2 | 1299.45 | 1299.45 | 1263.35 |
08 Nov 2024 | 1281.85 | 1288.8 | 1290 | 1259.6 |
07 Nov 2024 | 1287.15 | 1304.05 | 1311.6 | 1281 |
06 Nov 2024 | 1303 | 1272.25 | 1322 | 1251.5 |
Date | Price (₹) |
---|---|
21 Nov 2024 | 1194.55 |
19 Nov 2024 | 1213.95 |
18 Nov 2024 | 1193.35 |
14 Nov 2024 | 1226.05 |
13 Nov 2024 | 1245.7 |
12 Nov 2024 | 1263.1 |
11 Nov 2024 | 1288.2 |
08 Nov 2024 | 1281.85 |
07 Nov 2024 | 1287.15 |
06 Nov 2024 | 1303 |
Market Value
₹ 0
Asset Value
₹ 0
* All values are in Rupees
Historical Revenue of Dr Reddys Laboratories Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
No data available
* All values are in ₹ crore
Historical Net Profit of Dr Reddys Laboratories Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
No data available
* All values are in ₹ crore
DRL slips after Hyderabad facility gets 7 observations from USFDA
The GMP inspection was conducted from 13 November 2024 to 19 November 2024. The USFDA issu...
21 Nov 202410:23
DRL's Hyderabad facility gets 7 observations from USFDA
The GMP inspection was conducted from 13 November 2024 to 19 November 2024. The USFDA issu...
20 Nov 202410:40
Mexican health regulator imposes penalty on Dr Reddy's
Dr Reddys Laboratories has received an order dated 12 November 2024, from COFEPRIS (Comisi...
14 Nov 202409:22
Dr Reddys Laboratories Ltd spurts 2.25%
Dr Reddys Laboratories Ltd is up for a third straight session in a row. The stock is quoti...
06 Nov 202413:05
Dr Reddy's Q2 PAT slides 15% YoY to Rs 1,255 crore
Total revenue from operations stood at Rs 8,038.2 crore in Q2 FY25, up 16.45% YoY, primari...
05 Nov 202417:35
Aurigene Oncology receives nod for Phase 2 clinical trial for Ribrecabtagene autoleucel
Aurigene Oncology, a wholly-owned subsidiary of Dr. Reddy's Laboratories has announced the...
08 Oct 202418:16
Unlimited trading at just
Rs. 199*